SOLUTIONS

Clinical Success and Therapy Success

Two ways in. Clinical Success carries the trial endpoint and keeps the evidence running after the trial closes. Therapy Success covers launch, adoption and adherence, and builds the real-world evidence that underpins market access and reimbursement. Underneath both, the data is collected once and reused across the life of the asset.

Talk to usSee case studies

The two ways in

We work with life sciences companies across the life cycle of a product. Clinical teams use our eCOA and patient finding solutions to reach higher endpoint collection adherence and shorter throughput times. Medical and market access teams use us to collect the evidence that underpins reimbursement and market access files. Commercial teams use our patient support programs and remote monitoring to reach quicker adoption and higher adherence.

Whichever way you come in, the same data endpoint sits underneath. What it does at each stage of the life cycle is set out further down this page.

CLINICAL SUCCESS

Your endpoint, carried — outcome assessments for trials where the patient's own report is the result, the recruitment work that fills them, and the registries that keep the evidence running after the trial closes.

eCOA

Electronic clinical outcome assessments, purpose-built for the indication, delivered by a therapeutic-area team with the trial service around them.

Patient Finding

Finding and reaching eligible patients so trials enroll on time.

Real-World Evidence

Federated real-world data registries, built with hospitals and clinical leaders.

THERAPY SUCCESS

Your launch, built — the right patients found, started and kept on therapy, with the real-world evidence that underpins market access and reimbursement.

Patient Support Programs

Programs that help patients and doctors start a therapy, adapt when needed and achieve adherence.

Remote Monitoring & Clinical Pathways

Digital care pathways and remote monitoring for hospital teams.

Real-World Evidence for Market Access

Evidence built for reimbursement dossiers, HTA submissions and the Joint Clinical Assessment, and the medical insight that comes with it.

What the evidence does at each stage

The same collection serves a different purpose at every stage. Each row below names what the data is doing there, and all of it comes from one instrument.

What the evidence does at each lifecycle stage Clinical Success Market access Therapy Success Phase I–III Market access & reimbursement Launch & adoption Adherence Defends the endpoint Feeds the HTA dossier Supports medical education Measures persistence One evidence base, collected once

One instrument, four jobs

A validated outcome measure built to carry a trial endpoint does not stop being useful at approval. The same instrument, unchanged, does four different jobs across the life of the asset.

One validated instrument doing four jobs across the lifecycle Phase I–III 1 PRO endpoint defended Market access 2 HTA dossier input Launch & adoption 3 Medical education material Adherence 4 Persistence measured

Pharma and medtech follow the same shape

The regulatory language differs. A device runs a clinical evaluation rather than a phase program, and its post-market clinical follow-up is a standing MDR obligation rather than a commercial choice. The continuum underneath is the same, which is why one platform serves both.

Pharmaceutical and device programs map onto the same continuum DEVELOPMENT ACCESS LAUNCH POST-MARKET Pharma Phase I–III HTA & pricing Launch & adoption Adherence Medtech Clinical evaluation Reimbursement Market introduction Post-market follow-up

Start with reaching out

Whether you are designing a trial, building a reimbursement dossier or planning a launch: tell us where your asset is, and we will show you what we would do and what it would take.

Get in touch